Mobia Medical, Inc.

Mobia Medical, Inc. is a U.S.-based medical device company focused on stroke recovery. Its core product is the Vivistim Paired Vagus Nerve Stimulation System, which is used to support therapy for chronic ischemic stroke survivors with upper-extremity motor impairment.

— Mobia Medical, Inc.
%
Vivistim System90% Implantable neurostimulation system used in stroke rehabilitation therapy.
Accessories and replenishment products10% Consumable and replacement items sold alongside the installed base.

The company sells primarily to primary and comprehensive stroke centers in the United States, where the Vivistim System...

  • Primary stroke centersprimary

    Hospitals that perform most Vivistim implants and buy the system for stroke recovery programs.

  • Comprehensive stroke centersprimary

    Higher-acuity stroke hospitals that adopt the system for eligible chronic stroke patients.

  • Group purchasing organizations and IDNssecondary

    Buying groups that negotiate pricing and contract access for affiliated hospitals and ASCs.

  • Therapy and neurorehabilitation sitessecondary

    Facilities that support post-implant rehabilitation and help drive therapy utilization.

  • Payors and coverage decision-makerssecondary

    Private and governmental payors that influence adoption through reimbursement coverage.

Mobia Medical generates substantially all of its revenue in the United States, where it sells the Vivistim System to...

  • Substantially all revenue comes from the United States
  • Commercial focus is on U.S. primary and comprehensive stroke centers
  • Therapy adoption depends on nearby neurorehabilitation networks
  • GPO and IDN contracting shapes access across U.S. hospitals
  • Third-party manufacturing and suppliers support the U.S. business

The company is focused on expanding commercial reach, adding stroke centers, and increasing awareness of Vivistim...

01
Expand commercial coverage in stroke centersshort-term

The product is sold into a concentrated hospital channel, so more field coverage can increase implants and reorders.

02
Improve payer coverage and reimbursementmedium-term

Coverage policies directly affect hospital willingness to adopt and patients' access to therapy.

03
Support clinical evidence and regulatory workmedium-term

Clinical validation and regulatory compliance reinforce adoption in a specialized medical device market.

04
Scale supply chain and manufacturing capacitymedium-term

Third-party manufacturing must keep pace with demand and quality requirements.

Mobia Medical faces commercialization risk because adoption depends on hospital contracting, reimbursement, and...

high

GPO and IDN contracting pressure

Buying groups negotiate category-by-category and can force lower prices or fewer vendors.

Scope
U.S. hospital channel
Materiality
high
high

Reimbursement and coverage risk

Adoption depends on payer policies for procedures using Vivistim.

Scope
Private and governmental payors
Materiality
high
high

Third-party manufacturing and supplier dependence

Single-source or limited suppliers can delay shipments, raise costs, or cause recalls.

Scope
Contract manufacturers and component suppliers
Materiality
high
high

Ongoing losses and capital needs

Commercial expansion, clinical work, and public-company costs can require additional funding.

Scope
Growth-stage medical device commercialization
Materiality
high
medium

Competitive and technology risk

Larger medical device and robotics companies have greater scale, resources, and relationships.

Scope
Stroke prevention and stroke care markets
Materiality
medium
Stock compensation and common stock valuation
Reported operating expenses and equity valuation
Revenue timing for Vivistim system sales
Quarterly revenue comparability
Operating leases
Balance sheet and operating expense recognition
Convertible notes and warrant liabilities
Net income volatility
Purchase commitments and supplier obligations
Cash flow and working capital

: 16.6.2026